fda compounding semaglutide crackdown 2025 news The growing availability of compounded GLP-1 weight-loss drugs has prompted warnings from doctors and the U.S. Food and Drug Administration. Link in comments⬇️ Last month, the FDA issued

At TrimRx, we provide personalized, doctor-supervised programs to help you finally achieve your health goals in 2026

Do you stay the course

Some of these may be cheaper out-of-pocket, while others may be more expensive (but cheaper if theyre covered by your insurance)

It's not clear whether OrderlyMeds' approach will work, but the telehealth platform is one of several companies testing the FDA's rules by continuing to make and sell the compounded drugs

Originally developed to manage type 2 diabetes, GLP-1 receptor agonists have gained popularity for their appetite-suppressing and weight-loss effects, with the study finding that most prescriptions are now issued to women without diabetes

The dramatic appetite suppression of early weeks feels remarkable because it contrasts so strongly with previous experience